Let’s Get Ready to CAR-T: Management of Immunotherapy Toxicities

<p>Victoria R. Milano, Pharm.D., BCPS, (<a href='https://twitter.com/VMilanoPharmD'>@VMilanoPharmD</a>) describes the mechanism of immune checkpoint inhibitor and CAR T-cell therapy toxicities, reviews the most common types of toxicities and risk factors associated with immunotherapy treatments and discuss literature and guideline recommendations for the management of immunotherapy toxicities.</p> <p>For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs <a href='https://twitter.com/MayoPharmRes'>@MayoPharmRes</a> or the host, Garrett E. Schramm, Pharm.D., <a href='https://twitter.com/garrett_schramm'>@garrett_schramm</a> on Twitter!</p> <p>You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at <a href='https://ce.mayo.edu/'>https://ce.mayo.edu/</a> or on Twitter <a href='https://twitter.com/MayoMedEd'>@MayoMedEd</a>. </p>